U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07052838) titled 'Efficacy and Safety of HSK392975 in Anti-C5 Treated PNH Patients With Anemia' on June 29.
Brief Summary: The purpose of this study is to evaluate the efficacy of HSK39297 tablets in paroxysmal nocturnal hemoglobinuria patients with anemia after stable treatment of anti-C5 antibody.
Study Start Date: May 12
Study Type: INTERVENTIONAL
Condition:
Paroxysmal Nocturnal Haemoglobinuria (PNH)
Intervention:
DRUG: HSK39297 tablets
200mg QD
Recruitment Status: RECRUITING
Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....